AKEBIA THERAPEUTICS, INC. Impairment of Intangible Assets (Excluding Goodwill)
AKEBIA THERAPEUTICS, INC. (AKBA) reported Impairment of Intangible Assets (Excluding Goodwill) of $0 for the 12-month period ending 2022-12-31, per its 10-K/A filed 2023-08-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2023-08-28
- AKEBIA THERAPEUTICS, INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2021-12-31 was $0.00.
- AKEBIA THERAPEUTICS, INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2021-09-30 was $0.00.
- AKEBIA THERAPEUTICS, INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2020-12-31 was -$1.10M.
- AKEBIA THERAPEUTICS, INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2020-09-30 was $0.00.
- AKEBIA THERAPEUTICS, INC. impairment of intangible assets (excluding goodwill) for fiscal 2022 was $0.00.
- AKEBIA THERAPEUTICS, INC. impairment of intangible assets (excluding goodwill) for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- AKEBIA THERAPEUTICS, INC. impairment of intangible assets (excluding goodwill) for fiscal 2020 was $114.42M.
- AKEBIA THERAPEUTICS, INC. impairment of intangible assets (excluding goodwill) for fiscal 2019 was $0.00.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month | Impairment of Intangible Assets (Excluding Goodwill) 9 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K/A · filed 2023-08-28 | ||||
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $0.00 derived: sum of 2 quarters · filed 2023-08-28 | $0.00 10-K/A · filed 2023-08-28 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-05 | ||||
| 2020-12-31 | -$1.10M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | -$1.10M derived: sum of 2 quarters · filed 2023-08-28 | $114.42M 10-K/A · filed 2023-08-28 | $115.53M 10-K · filed 2021-02-25 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $115.53M 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | $115.53M 10-Q · filed 2021-08-05 | ||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $0.00 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-10 | ||||
| 2018-12-31 | $0.00 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |